ISK-018

PCSK9; LDLR

PCSK9 is a crucial protein in the regulation of plasma cholesterol homeostasis. It binds low density lipoprotein receptor (LDL R) to enhance the degradation of LDL R. Therefore, inhibition of PCSK9 has been considered a promising strategy to prevent the receptor from being degraded and promote removal of LDL cholesterol from circulation.

96 tests

20-0.04 μg/mL

This inhibitor screening ELISA pair is designed to facilitate the identification and characterization of new PCSK9 pathway inhibitors. This assay employs a simple colorimetric ELISA platform, which measures the binding between immobilized human LDL R and in-house developed biotinylated PCSK9 protein. This product is uniquely suitable for rapid high-throughput screening of putative PCSK9 inhibitors. Briefly, we provide you with a biotinylated human PCSK9 protein, a human LDL R protein, an anti-PCSK9 neutralizing antibody (as method verified Reference), and Streptavidin-HRP reagent.
Your experiment will include 4 simple steps:
1. Coat the plate with human LDL R.
2. Add your molecule of interest to the plates.
3. Add human PCSK9-Biotin to the plates.
4. Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
Finally, the ability of your compound to inhibit PCSK9: LDL R binding will be determined by comparing OD readings among different experimental groups.

This pair is useful for screening for inhibitors of human PCSK9 binding to human LDL R.

See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Upon receipt, please store all items at -70°C.
After reconstitution, the stock solution should be kept at -70°C.

Serial dilutions of anti-PCSK9 neutralizing antibody (1:2 serial dilutions, from 20 μg/mL to 0.04 μg/mL or 133.33 nM to 0.26 nM) were added into Biotinylated PCSK9: LDL R binding reactions. Background was subtracted from data points prior to log transformation and curve fitting.